References
- Azzi M, Charest PG, Anger S, Rousseau G, Kohout T, Bouvier M. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 2003, 100, 11406–11411.
- Fuxe K, Agnati LF. Receptor–Receptor Interactions. A New Intramembrane Integrative Mechanism. London UK, MacMillan Press, 1987.
- Galandrin S, Bouvier M. Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006, 70, 1575–1584.
- Hejnová L, Tucek S, el-Fakahany EE. Positive and negative allosteric interactions on muscarinic receptors. Eur J Pharmacol 1995, 291, 427–430.
- Mukhopadhyay S, Howlett AC. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 2005, 67, 2016–2024.
- Violin JD, Lekowitz RJ. β-Arrestin-biased ligands at seven transmembrane receptors. Trends Pharmacol Sci 2007, 28, 416–422.
- Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ. Independent beta-arrestin 2 and G protein mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 2003, 100, 10782–10787.